Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

Article content

SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special meeting of shareholders, originally scheduled to be held on January 16, 2026 (the “Meeting”), to a later date to be announced. Aptose will hold the rescheduled Meeting as soon as practicable in January 2026. No changes are expected to be made to the record date of the Meeting, being the close of business on December 12, 2025, or to the matters to be put before shareholders at the Meeting, including the previously announced continuance of Aptose from the Canada Business Corporations Act to the Business Corporations Act (Alberta) (“ABCA”) (the “Continuance”) and the subsequent acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd. (together, the “Hanmi Purchasers”), by way of a statutory plan of arrangement under the ABCA (the “Arrangement” and, together with the Continuance, the “Transaction”).

Article content

Article content

Aptose has determined to reschedule the Meeting after it receives final clearance of the proxy statement from the United States Securities and Exchange Commission (“SEC”). Following the clearance from the SEC, Aptose will announce the new date, time and virtual details for the Meeting. Aptose intends to mail to all shareholders, and to make available under its profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov, the proxy statement, form of proxy, letter of transmittal along with any additional required disclosure in connection with the Meeting.

Article content

Article content

Article content

On December 12, 2025, Aptose obtained an interim order from the Court of King’s Bench of Alberta (the “Court”) authorizing the holding of the Meeting and matters relating to the conduct of the Meeting.

Article content

The Company’s board of directors unanimously recommends that the holders of Aptose common shares vote FOR the special resolutions approving the Continuance and the Arrangement at the Meeting.

Article content

About Aptose

Article content

Aptose Biosciences Inc. is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.

Article content

Article content

Forward Looking Statements

Article content

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. This information includes, but is not limited to, statements concerning our objectives, our strategies to achieve those objectives, as well as statements made with respect to management’s beliefs, plans, estimates, projections and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “expects”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “intends”, “anticipates”, “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances. Forward-looking information in this news release include, among other things, statements relating to Aptose’s business in general; statements relating to the postponed Meeting and the timing thereof, the expected impact on the record date, the clearance from the SEC and the timing thereof the mailing of the proxy statement, form of proxy, letter of transmittal along with any additional required disclosure in connection with the Meeting and the timing thereof.